Apixaban is under clinical development by Taho Pharmaceuticals and currently in Phase I for Pulmonary Embolism. According to GlobalData, Phase I drugs for Pulmonary Embolism have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Apixaban’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Apixaban is under development for the treatment of stroke, deep vein thrombosis (DVT) and pulmonary embolism (PE). The drug candidate acts by targeting coagulation factor X and is administered through oral route in the form of dissolving film. It is developed based on Transmucosal DDS platform.
For a complete picture of Apixaban’s drug-specific PTSR and LoA scores, buy the report here.